COVID‐19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network
Main finding · COVID-19 vaccine uptakeResult — go to the resultAdjusted odds ratio 0.68 95% CI 0.65–0.72Authors' conclusion
Some patients who are vaccine and booster hesitant eventually receive a vaccine dose
Study context
- Population
- Patients of 108 rheumatology practices in a practice-based network surveyed December 2021 to December 2022
- Participants
- 61,158 patients
- Exposure
- Patients with vs without autoimmune and inflammatory rheumatic diseases (AIIRDs)
- Outcome
- COVID-19 vaccine uptake, reasons for hesitancy, and self-reported flare
Methodological detailstablet-based survey, 108 rheumatology practices, multivariable logistic regression
- Tablet-based survey
- 108 rheumatology practices
- Multivariable logistic regression
Main finding
COVID-19 vaccine uptake
Adjusted odds ratio
0.68
95% CI 0.65–0.72
AIIRDvs Without AIIRD
aOR 0.68 (95% CI 0.65–0.72)
As reported in the abstract
- At least one vaccine dose (all patients)
- 89%
- At least one booster (of the vaccinated)
- 68%
- Vaccinated patients with AIIRDs vs unvaccinated
- 44% vs 56%
Observational data: associations, not effects.
Further findings
Vaccine hesitancy
Booster hesitancy
Reasons for hesitancy
- Safety concerns (vaccine hesitancy)
- 28%
- Side effects (vaccine hesitancy)
- 23%
- Lack of physician recommendation (booster hesitancy)
- 23%
Hesitant patients later reporting receiving a dose
- Vaccine hesitant
- 12%
- Booster hesitant
- 39%
Safety
| Outcome | aOR (95% CI) | |
|---|---|---|
| Self-reported flare or worsening disease | 0.99 (0.94–1.05) | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
COVID‐19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network. Arthritis Care Res (Hoboken). Published 12 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →